JP7689518B2 - グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル - Google Patents

グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル Download PDF

Info

Publication number
JP7689518B2
JP7689518B2 JP2022519782A JP2022519782A JP7689518B2 JP 7689518 B2 JP7689518 B2 JP 7689518B2 JP 2022519782 A JP2022519782 A JP 2022519782A JP 2022519782 A JP2022519782 A JP 2022519782A JP 7689518 B2 JP7689518 B2 JP 7689518B2
Authority
JP
Japan
Prior art keywords
glycocalyx
disease
biomarkers
ftx
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022519782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549373A (ja
JPWO2021062298A5 (https=
JP2022549373A5 (https=
Inventor
ジョセフィーノ・ビー・トゥナック
Original Assignee
アーテレズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーテレズ・インコーポレイテッド filed Critical アーテレズ・インコーポレイテッド
Publication of JP2022549373A publication Critical patent/JP2022549373A/ja
Publication of JPWO2021062298A5 publication Critical patent/JPWO2021062298A5/ja
Publication of JP2022549373A5 publication Critical patent/JP2022549373A5/ja
Application granted granted Critical
Publication of JP7689518B2 publication Critical patent/JP7689518B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022519782A 2019-09-27 2020-09-25 グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル Active JP7689518B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962907389P 2019-09-27 2019-09-27
US62/907,389 2019-09-27
PCT/US2020/052912 WO2021062298A1 (en) 2019-09-27 2020-09-25 Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Publications (4)

Publication Number Publication Date
JP2022549373A JP2022549373A (ja) 2022-11-24
JPWO2021062298A5 JPWO2021062298A5 (https=) 2023-10-11
JP2022549373A5 JP2022549373A5 (https=) 2023-10-11
JP7689518B2 true JP7689518B2 (ja) 2025-06-06

Family

ID=75166872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519782A Active JP7689518B2 (ja) 2019-09-27 2020-09-25 グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル

Country Status (7)

Country Link
US (1) US20220390454A1 (https=)
EP (1) EP4034164A4 (https=)
JP (1) JP7689518B2 (https=)
AU (1) AU2020356626A1 (https=)
CA (1) CA3155843A1 (https=)
IL (1) IL291667A (https=)
WO (1) WO2021062298A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US12105099B2 (en) 2021-04-28 2024-10-01 Diotex Diagnostics, Llc Methods and devices for quantitatively estimating syndecan-1
CN115389773A (zh) * 2022-09-22 2022-11-25 无锡市第二人民医院 糖萼脱落标志物在诊断和防治初发的2型糖尿病肾病早期肾损伤的应用
WO2025049608A1 (en) * 2023-08-28 2025-03-06 Calroyhealth Sciences, Llc Compositions and methods to protect and enhance structural and functional integrity of the intestinal glycocalyx

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006030183A (ja) 2004-07-07 2006-02-02 F Hoffmann La Roche Ag １型および２型糖尿病に対する、ｐ１ｇｆに基づく多重マーカーパネル
JP2010515023A (ja) 2006-12-22 2010-05-06 アボット・ラボラトリーズ 心血管系自己免疫疾患パネルおよびその使用方法
JP2014505259A (ja) 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2437491T3 (es) * 2003-10-10 2014-01-10 Alchemia Oncology Pty Limited Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
EP2302395B1 (en) * 2006-06-07 2015-04-15 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2011115783A1 (en) * 2010-03-15 2011-09-22 Oregon Health & Science University Methods for assessing the risk of cardiovascular disease
US9086412B2 (en) * 2012-12-31 2015-07-21 University Of Louisville Research Foundation, Inc. Extracellular vesicle-associated protein markers of cancer
EP2965088B1 (en) * 2013-03-04 2018-12-05 IQ Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
WO2016123163A2 (en) * 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2016126662A1 (en) * 2015-02-03 2016-08-11 Kardiatonos, Inc. Compounds for the prevention and treatment of vascular disease
WO2016164534A1 (en) * 2015-04-09 2016-10-13 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2016176089A1 (en) * 2015-04-29 2016-11-03 Kardiatonos, Inc. Methods and compositions for reversing disruption of the glycocalyx, inflammation, and oxidative damage
WO2017136652A1 (en) * 2016-02-04 2017-08-10 Tarveda Therapeutics, Inc. Stapled peptide conjugates and particles
JP7420557B2 (ja) * 2017-03-07 2024-01-23 オルト－クリニカル ダイアグノスティックス インコーポレイテッド 分析物を検出するための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006030183A (ja) 2004-07-07 2006-02-02 F Hoffmann La Roche Ag １型および２型糖尿病に対する、ｐ１ｇｆに基づく多重マーカーパネル
JP2010515023A (ja) 2006-12-22 2010-05-06 アボット・ラボラトリーズ 心血管系自己免疫疾患パネルおよびその使用方法
JP2014505259A (ja) 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法

Also Published As

Publication number Publication date
WO2021062298A1 (en) 2021-04-01
JP2022549373A (ja) 2022-11-24
IL291667A (en) 2022-05-01
EP4034164A1 (en) 2022-08-03
CA3155843A1 (en) 2021-04-01
EP4034164A4 (en) 2024-01-24
AU2020356626A1 (en) 2022-04-14
US20220390454A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
JP7689518B2 (ja) グリコカリックス破壊の多因子オントロジーによる疾患をターゲティングしたバイオマーカーパネル
KR20210013297A (ko) pKal 매개 장애의 평가, 검정 및 치료
JP7091413B2 (ja) 抗血栓療法および止血療法のための組成物および方法
ES2857552T3 (es) Inmunoensayo para detectar cininógenos de alto peso molecular escindido
JP6198277B2 (ja) 血液凝固促進に使用するための化合物
E. Mirrakhimov et al. Primary antiphospholipid syndrome and pulmonary hypertension
JPWO2021062298A5 (https=)
EP3117356B1 (en) Diagnostic marker for treatment of cerebral ischemia
US20220288110A1 (en) Drug treatment and biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption
JP4374248B2 (ja) アテローム性動脈硬化症の治療用の手段
JP2001091517A (ja) 血液中の低比重リポ蛋白（ｌｄｌ）もしくは変性低比重リポ蛋白の検出方法
US8852879B2 (en) Materials and methods for the detection of nitrated fibrinogen
US20090042800A1 (en) Assay
Duering et al. Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke
US20210346482A1 (en) Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
US7981619B2 (en) Composition for prevention, treatment, and diagnosis of chronic obstructive pulmonary disease (COPD)
Ortel et al. Antiphospholipid Syndrome
US20050244905A1 (en) Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation
JP7794759B2 (ja) インフラマソーム関連疾患又は病態を処置するための組成物及び方法
JP4451518B2 (ja) ハイブリッド細胞、モノクローナル抗体、製造方法および測定方法
WO2017167763A1 (en) Methods for diagnosis of haemorrhagic atherothrombotic plaques
Rounds Anticoagulation in Antiphospholipid Antibody Syndrome
CH694905A5 (it) Peptidi derivati dalla proteina HMGB1 per l'immunoterapia attiva nell'infiammazione sistematica letale.
JP2023508568A (ja) 病原性抗リン脂質抗体の検出法及び阻害剤の同定法
Maat Natural pathways for factor XII activation: Implications for hereditary angioedema

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230925

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250326

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250527

R150 Certificate of patent or registration of utility model

Ref document number: 7689518

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150